ALGS News - Candlesense

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through be...

Leadership

3 days ago

Read more globenewswire

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving pati...

What is the potential impact of this equity issuance on the company’s leverage ratios and any existing covenants tied to share count or market‑cap thresholds? Will the compensation committee’s decision be disclosed in the upcoming Form 8‑K, and does it contain any forward‑looking statements about future hiring plans? How might the grant affect the company’s cash‑flow outlook if the options are exercised in the near term?

Compensation

8 days ago

Read more globenewswire

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes...

What catalysts (e.g., interim data releases, regulatory milestones) should traders monitor for short‑term trading opportunities? How might this trial affect the valuation of peer companies with HBV pipelines (e.g., Inovio, Virion, Gilead)? What are the potential dilution effects from upcoming financing rounds or equity offerings to fund the trial?

Clinical trials

10 days ago

Read more globenewswire

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thr...

How will the recent business progress affect the company’s long‑term strategic objectives and share price trajectory? What macro‑economic or sector trends could intersect with Aligos’ reported performance? Did the release mention any non‑dilutive financing sources, such as grants or milestone payments?

Earnings

17 days ago

Read more globenewswire